192 related articles for article (PubMed ID: 22555372)
1. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.
Jin J; Chang Y; Wei W; He YF; Hu SS; Wang D; Wu YJ
Acta Pharmacol Sin; 2012 May; 33(5):701-9. PubMed ID: 22555372
[TBL] [Abstract][Full Text] [Related]
2. Synergetic Effect of EP1 Receptor Antagonist and (-)-Epigallocatechin-3-gallate in Hepatocellular Carcinoma.
Yang H; Wang M; Sun H; Zhu S; Jin J
Pharmacology; 2019; 104(5-6):267-275. PubMed ID: 31434088
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
Han C; Michalopoulos GK; Wu T
J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686
[TBL] [Abstract][Full Text] [Related]
4. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.
Zapf MA; Kothari AN; Weber CE; Arffa ML; Wai PY; Driver J; Gupta GN; Kuo PC; Mi Z
Surgery; 2015 Oct; 158(4):1039-47; discussion 1047-8. PubMed ID: 26189955
[TBL] [Abstract][Full Text] [Related]
5. Investigation of folate-modified EGCG-loaded thermosensitive nanospheres inducing immunogenic cell death and damage-associated molecular patterns in hepatocellular carcinoma.
He L; Peng L; Wang L; Jiang X; Sun X; Li H; Lin T; Wu Z; Lin S
Biochem Biophys Res Commun; 2024 Jun; 714():149976. PubMed ID: 38677007
[TBL] [Abstract][Full Text] [Related]
6. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E₂ receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells.
Bai X; Wang J; Zhang L; Ma J; Zhang H; Xia S; Zhang M; Ma X; Guo Y; Rong R; Cheng S; Shu W; Wang Y; Leng J
Int J Oncol; 2013 May; 42(5):1833-41. PubMed ID: 23525457
[TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin gallate induces chemopreventive effects on rats with diethylnitrosamine‑induced liver cancer via inhibition of cell division cycle 25A.
Tang Y; Cao J; Cai Z; An H; Li Y; Peng Y; Chen N; Luo A; Tao H; Li K
Mol Med Rep; 2020 Nov; 22(5):3873-3885. PubMed ID: 33000276
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation.
Wubetu GY; Shimada M; Morine Y; Ikemoto T; Ishikawa D; Iwahashi S; Yamada S; Saito Y; Arakawa Y; Imura S
J Gastroenterol Hepatol; 2016 Jan; 31(1):256-64. PubMed ID: 26241688
[TBL] [Abstract][Full Text] [Related]
10. Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713.
Norel X; de Montpreville V; Brink C
Prostaglandins Other Lipid Mediat; 2004 Oct; 74(1-4):101-12. PubMed ID: 15560119
[TBL] [Abstract][Full Text] [Related]
11. Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway.
Darweish MM; Abbas A; Ebrahim MA; Al-Gayyar MM
J Pharm Pharmacol; 2014 Jul; 66(7):1032-45. PubMed ID: 24611903
[TBL] [Abstract][Full Text] [Related]
12. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
[TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
14. [Prostaglandin E2 promotes hepatocellular carcinoma cell proliferation through EP2 prostanoid receptor].
Guo D; Chen NN; Hou LB; Lei LS
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1564-7. PubMed ID: 21945767
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis.
Hu S; Sun W; Wei W; Wang D; Jin J; Wu J; Chen J; Wu H; Wang Q
Anticancer Drugs; 2013 Feb; 24(2):140-9. PubMed ID: 23069790
[TBL] [Abstract][Full Text] [Related]
16. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells.
Han B; Liu SH; Guo WD; Zhang B; Wang JP; Cao YK; Liu J
World J Gastroenterol; 2015 Sep; 21(33):9727-35. PubMed ID: 26361419
[TBL] [Abstract][Full Text] [Related]
17. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
18. Akebia trifoliata (Thunb.) Koidz Seed Extract inhibits human hepatocellular carcinoma cell migration and invasion in vitro.
Lu WL; Yang T; Song QJ; Fang ZQ; Pan ZQ; Liang C; Jia DW; Peng PK
J Ethnopharmacol; 2019 Apr; 234():204-215. PubMed ID: 30528882
[TBL] [Abstract][Full Text] [Related]
19. A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.
Makita H; Mutoh M; Maruyama T; Yonemoto K; Kobayashi A; Fujitsuka H; Toida M; Shibata T; Miyamoto S; Yasui Y; Suzuki R; Wakabayashi K; Tanaka T
Carcinogenesis; 2007 Mar; 28(3):677-84. PubMed ID: 17052996
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor.
Taub M; Parker R; Mathivanan P; Ariff MA; Rudra T
Am J Physiol Renal Physiol; 2014 Sep; 307(5):F539-50. PubMed ID: 25007872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
